Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Queensland Health
US Department of Justice
Baxter
Citi
Colorcon
Daiichi Sankyo
Deloitte

Generated: May 28, 2018

DrugPatentWatch Database Preview

VFEND Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Vfend, and when can generic versions of Vfend launch?

Vfend is a drug marketed by Pf Prism Cv and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-nine patent family members in forty-six countries.

The generic ingredient in VFEND is voriconazole. There are fourteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the voriconazole profile page.
Drug patent expirations by year for VFEND
Medical Subject Heading (MeSH) Categories for VFEND
Synonyms for VFEND
(+/-)-Voriconazole
(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol
(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol
(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol
(2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2R,3S)-2,3-bis(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
137234-62-9
173967-54-9
234V629
2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-
4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-rel-
4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-
AB0013963
AB00639948_07
AB00639948_08
AB00639948-04
AB00639948-06
AC-823
AC1L2GHR
AC1Q4O6I
AKOS005145705
AN-15471
BC660191
BCEHBSKCWLPMDN-MGPLVRAMSA-N
BCPP000019
BDBM50333117
C07622
C16H14F3N5O
CAS-137234-62-9
CCG-100941
CHEBI:10023
CHEMBL638
CPD000466350
CS-1227
CTK8E9205
D00578
D0N3VR
DB00582
DRG-0301
DSSTox_CID_26485
DSSTox_GSID_46485
DSSTox_RID_81656
DTXSID5046485
FT-0082604
FT-0631154
HE063767
HMS2051N09
HMS3260M22
HY-76200
I992
J-006986
J10329
JFU09I87TR
KB-62693
KS-0000001W
KS-1157
LS-181799
MFCD00905717
MFCD20488064
MLS000759464
MLS001424082
MLS006010028
MolPort-003-850-863
NC00191
NCGC00164622-01
NCGC00164622-02
NCGC00164622-04
NCGC00260835-01
NSC-759888
NSC759888
Pfizer
Pfizer brand of voriconazole
Pharmakon1600-01502346
PL045227
RT-016239
s1442
SAM001246664
SC-25806
SCHEMBL36233
SMR000466350
SYN3012
TL8000858
Tox21_112241
Tox21_112241_1
Tox21_500150
UK 109,496
UK 109496
UK-109,496
UK-109496
UK109496
UNII-JFU09I87TR
UNII-USG4B1CD29 component BCEHBSKCWLPMDN-MGPLVRAMSA-N
VCZ
Vfend (TN)
VFEND I.V.
Vfend, Voriconazole
Voriconazol
Voriconazole
Voriconazole - Vfend
Voriconazole (JAN/USAN/INN)
Voriconazole (JP17/USAN/INN)
Voriconazole [USAN:INN:BAN]
Voriconazole 2.0 mg/ml in Methanol
Voriconazole in combination with MGCD290
Voriconazole related compound A
Voriconazole related compound A RS [USP]
Voriconazole, (+/-)-
Voriconazole, >=98% (HPLC)
Voriconazole, European Pharmacopoeia (EP) Reference Standard
Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material
Voriconazole, United States Pharmacopeia (USP) Reference Standard
Voriconazole, VETRANAL(TM), analytical standard
Voriconazolum
Vorikonazole
VRC
W-5208
Z2616414875
ZINC14864

US Patents and Regulatory Information for VFEND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv VFEND voriconazole FOR SUSPENSION;ORAL 021630-001 Dec 19, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-002 May 24, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pf Prism Cv VFEND voriconazole INJECTABLE;IV (INFUSION) 021267-001 May 24, 2002 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-001 May 24, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for VFEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv VFEND voriconazole TABLET;ORAL 021266-001 May 24, 2002 ➤ Sign Up ➤ Sign Up
Pf Prism Cv VFEND voriconazole FOR SUSPENSION;ORAL 021630-001 Dec 19, 2003 ➤ Sign Up ➤ Sign Up
Pf Prism Cv VFEND voriconazole FOR SUSPENSION;ORAL 021630-001 Dec 19, 2003 ➤ Sign Up ➤ Sign Up
Pf Prism Cv VFEND voriconazole INJECTABLE;IV (INFUSION) 021267-001 May 24, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VFEND
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2010-10-08
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2008-09-12
➤ Subscribe Tablets 50 mg and 200 mg ➤ Subscribe 2008-04-14

or, see our see our flat-rate plans

Supplementary Protection Certificates for VFEND

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030 France ➤ Sign Up PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319
2003005 Lithuania ➤ Sign Up PRODUCT NAME: VORICONAZOLIS; REGISTRATION NO/DATE: 02/7890/8 20021002
C/GB02/031 United Kingdom ➤ Sign Up PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Citi
Chinese Patent Office
Accenture
Merck
McKinsey
Farmers Insurance
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.